Australian Cancer Pioneer Richard Scolyer Dies at 59
The Spin
Narrative A
Brain cancer research has been stuck in neutral for two decades while other cancers have seen dramatic breakthroughs. The five-year survival rate for aggressive brain cancer remains below 5%, even as melanoma survival has surged past 50%. Coordinated, well-funded research teams are the only path forward — and the science Scolyer generated proves bold immunotherapy approaches deserve serious investment now.
Narrative B
Richard Scolyer didn't just face a terminal diagnosis — he turned it into a scientific breakthrough that will reshape brain cancer treatment for generations. His world-first immunotherapy regimen extended his life nearly two years beyond what standard treatment would have offered, and the clinical trial it sparked at Duke University means future patients will directly benefit. That's a legacy that transcends one life.
